Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Reema Health Secures $19M in Series B Funding to Expand Care Navigation Services

Reema Health Secures $19M in Series B Funding to Expand Care Navigation Services

Reema Health, a care navigation company specializing in complex patient populations, has raised $19 million in a series B funding round led by LRVHealth and Optum Ventures. The investment will fuel the company's expansion of partnerships and services, particularly in addressing the needs of Medicaid, Medicare, and dual-eligible patients.

NoahAI News12/2/2025
Novocure Announces Leadership Change, Promotes Veteran Executive to CEO Role

Novocure Announces Leadership Change, Promotes Veteran Executive to CEO Role

Novocure, the Swiss-based innovator in cancer treatment technology, has announced a significant leadership transition. Frank Leonard, a 15-year company veteran, has been appointed as the new Chief Executive Officer, effective immediately. This move comes as part of a sudden change in the company's top leadership, marking a pivotal moment for the firm known for its groundbreaking Tumor Treating Fields (TTFields) therapy.

NoahAI News12/2/2025
Tiziana Life Sciences to Spin Out IL-6 Drug into New Public Company, Citing Big Pharma Interest

Tiziana Life Sciences to Spin Out IL-6 Drug into New Public Company, Citing Big Pharma Interest

Tiziana Life Sciences has announced plans to create a new publicly listed immunology-focused spinout company centered on its IL-6 pathway drug, TZLS-501. This strategic move comes amid heightened industry interest in interleukin-6 (IL-6) targeted therapies, exemplified by Novartis' recent $1.4 billion acquisition of Tourmaline Bio.

NoahAI News12/2/2025
Imvax's Brain Cancer Cell Therapy Shows Promise in Phase 2b Trial, Despite Primary Endpoint Miss

Imvax's Brain Cancer Cell Therapy Shows Promise in Phase 2b Trial, Despite Primary Endpoint Miss

Imvax, a biotechnology company focused on developing innovative cancer treatments, has reported mixed results from its phase 2b trial for IGV-001, a personalized cell therapy for newly diagnosed glioblastoma patients. While the study failed to meet its primary endpoint of progression-free survival (PFS), the company is highlighting encouraging overall survival (OS) data as it prepares to engage with the FDA.

NoahAI News12/2/2025
Contingent Value Rights Gain Traction in Biotech M&A Deals Amid Market Turbulence

Contingent Value Rights Gain Traction in Biotech M&A Deals Amid Market Turbulence

In a volatile biotech market characterized by fluctuating stock prices and economic uncertainty, dealmakers are increasingly turning to contingent value rights (CVRs) to bridge valuation gaps and facilitate mergers and acquisitions. This decades-old financial tool has seen a resurgence in popularity, helping to catalyze a recent uptick in biotech deals and offering a potential lifeline to cash-strapped drug developers.

NoahAI News12/2/2025
Pharmaceutical Industry Grapples with Manufacturing Challenges as Companies Seek Alternative Solutions

Pharmaceutical Industry Grapples with Manufacturing Challenges as Companies Seek Alternative Solutions

In recent months, the pharmaceutical industry has been rocked by manufacturing issues at a key facility, leading to regulatory setbacks and prompting companies to seek alternative production solutions. The ex-Catalent plant in Bloomington, Indiana, now owned by Novo Nordisk, has become the epicenter of quality control concerns, affecting multiple drug manufacturers and their product approvals.

NoahAI News12/2/2025
Protego Biopharma Advances AL Amyloidosis Treatment with $130M Series B Funding

Protego Biopharma Advances AL Amyloidosis Treatment with $130M Series B Funding

Protego Biopharma, a San Diego-based biotech company, has successfully closed a $130 million Series B funding round to advance its innovative treatment for amyloid light-chain (AL) amyloidosis. The oversubscribed round, led by Novartis Venture Fund and Forbion, positions the company to push forward with pivotal clinical trials for its lead candidate, PROT-001.

NoahAI News12/2/2025
Regeneron Inks $275M Gene Editing Deal with Tessera Therapeutics for Alpha-1 Antitrypsin Deficiency Treatment

Regeneron Inks $275M Gene Editing Deal with Tessera Therapeutics for Alpha-1 Antitrypsin Deficiency Treatment

Regeneron Pharmaceuticals has announced a significant partnership with gene editing startup Tessera Therapeutics, marking a major investment in the development of novel treatments for alpha-1 antitrypsin deficiency (AATD). The collaboration, centered on Tessera's innovative gene writing technology, represents a $275 million commitment from Regeneron and underscores the growing interest in genetic medicine approaches to rare diseases.

NoahAI News12/2/2025
Pharmaceutical Industry Faces Widespread Layoffs Amid Strategic Shifts and Market Pressures

Pharmaceutical Industry Faces Widespread Layoffs Amid Strategic Shifts and Market Pressures

The pharmaceutical and biotech sectors are experiencing a significant wave of layoffs and restructuring as companies grapple with pipeline challenges, financial pressures, and strategic realignments. Major players like Novo Nordisk, Merck, and Bristol Myers Squibb have announced substantial workforce reductions, while smaller biotechs are also trimming headcounts to extend cash runways.

NoahAI News12/2/2025
Tanabe Pharma Emerges: Bain Capital's $3.3B Acquisition Reshapes Japanese Pharmaceutical Landscape

Tanabe Pharma Emerges: Bain Capital's $3.3B Acquisition Reshapes Japanese Pharmaceutical Landscape

In a significant move that marks a new era for one of Japan's oldest pharmaceutical companies, Mitsubishi Tanabe Pharma has rebranded as Tanabe Pharma following its ¥510 billion ($3.3 billion) acquisition by Bain Capital. The transition, which became effective on December 1, 2025, not only involves a name change but also signifies a strategic shift for the 350-year-old drugmaker as it aims to enhance its global recognition under new ownership.

NoahAI News12/2/2025
Microsize and Schedio Group to Acquire Lonza's Swiss Micronization Facility

Microsize and Schedio Group to Acquire Lonza's Swiss Micronization Facility

In a significant move that reshapes the landscape of particle engineering services, U.S.-based CDMO Microsize has partnered with Switzerland's Schedio Group to acquire Lonza's micronization facility in Monteggio, Switzerland. The deal, expected to close in the first quarter of 2024, marks a strategic expansion for Microsize and underscores the ongoing evolution in the pharmaceutical manufacturing sector.

NoahAI News12/2/2025
Omnicom-Interpublic Merger Finalizes, Reshaping Pharma Advertising Landscape

Omnicom-Interpublic Merger Finalizes, Reshaping Pharma Advertising Landscape

In a landmark move that reverberates through the pharmaceutical advertising sector, Omnicom and Interpublic Group have completed their $13.5 billion merger, creating the world's largest advertising agency. The deal, which closed on November 26, 2025, marks a significant shift in the industry landscape and brings with it substantial organizational changes and workforce reductions.

NoahAI News12/2/2025
«1...789...67»